Mild to moderate Alzheimer’s Disease
Conditions
Brief summary
Change from baseline in ADAS-Cog11 at Week 24, CIBIC+ at Week 24
Detailed description
Change from baseline in ADCS-ADL at Week 24, Change from baseline in NPI total score at Week 24, Occurence of AEs and SAEs, AESIs, AEs leading to study intervention discontinuation, AEs leading to study discontinuation, and AEs leading to death through Week 24, Incidence and severity of clinically significant changes in vital signs, ECG, C-SSRS, weight, and safety laboratory tests through Week 24
Interventions
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in ADAS-Cog11 at Week 24, CIBIC+ at Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in ADCS-ADL at Week 24, Change from baseline in NPI total score at Week 24, Occurence of AEs and SAEs, AESIs, AEs leading to study intervention discontinuation, AEs leading to study discontinuation, and AEs leading to death through Week 24, Incidence and severity of clinically significant changes in vital signs, ECG, C-SSRS, weight, and safety laboratory tests through Week 24 | — |
Countries
Finland, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Romania, Spain
Outcome results
None listed